Stay updated on Safety of Selonsertib, Firsocostat, & Cilofexor in NASH Clinical Trial
Sign up to get notified when there's something new on the Safety of Selonsertib, Firsocostat, & Cilofexor in NASH Clinical Trial page.

Latest updates to the Safety of Selonsertib, Firsocostat, & Cilofexor in NASH Clinical Trial page
- Check2 days agoChange DetectedAdded a new MedlinePlus Genetics topic: Non-alcoholic fatty liver disease, expanding core content.SummaryDifference0.2%
- Check9 days agoChange DetectedUpdated version to v3.2.0 and added a government-operating-status notice; removed the prior v3.1.0 tag.SummaryDifference2%
- Check17 days agoChange DetectedVersion upgraded to v3.1.0 with removal of a topic (Non-alcoholic fatty liver disease) and no other substantive updates.SummaryDifference0.3%
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedUpdated the page from v3.0.1 to v3.0.2, indicating a software release update; removed the 'Back to Top' element as part of the UI cleanup.SummaryDifference0.1%
- Check38 days agoChange DetectedThe web page has been updated to include information on non-alcoholic fatty liver disease and has been revised to version 3.0.1.SummaryDifference0.3%
- Check45 days agoChange DetectedThe web page has updated its facility name and location details, including the addition of specific drug information for Crizanlizumab and firsocostat, while removing several previous location-related terms and genetic information topics.SummaryDifference2%
Stay in the know with updates to Safety of Selonsertib, Firsocostat, & Cilofexor in NASH Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of Selonsertib, Firsocostat, & Cilofexor in NASH Clinical Trial page.